Skip to main content

MYRIAD GENETICS INC

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows for the

Condensed Consolidated Statements of Cash Flows (unaudited)

Nine months ended September 30,
20262025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(121.2)$(358.0)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization37.641.1
Non-cash lease expense3.26.6
Stock-based compensation expense22.932.4
Unrecognized tax benefits—(31.5)
Impairment of goodwill and long-lived assets5.4316.7
Other non-cash adjustments2.81.6
Changes in assets and liabilities:
Prepaid expenses and other current assets(5.0)(3.1)
Trade accounts receivable9.63.6
Inventory2.0(4.1)
Prepaid taxes10.52.6
Other assets(0.7)1.3
Accounts payable1.62.8
Accrued liabilities0.8(20.8)
Net cash used in operating activities(30.5)(8.8)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures(9.3)(10.9)
Capitalization of intangible assets(2.5)(10.5)
Net cash used in investing activities(11.8)(21.4)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock issued under stock-based compensation plans2.82.7
Payment of tax withheld for common stock issued under stock-based compensation plans(3.5)(6.1)
Proceeds from revolving credit facility—40.0
Repayment of revolving credit facility—(80.5)
Proceeds from the issuance of secured long-term credit facility—125.0
Fees associated with the issuance of secured long-term credit facility—(8.4)
Payment on finance leases(0.4)(0.3)
Net cash (used in) provided by financing activities(1.1)72.4
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash(0.1)0.7
Net (decrease) increase in cash, cash equivalents, and restricted cash(43.5)42.9
Cash, cash equivalents, and restricted cash at beginning of the period151.3111.9
Cash, cash equivalents, and restricted cash at end of the period$107.8$154.8
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.